Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.41 |
| ▸ | PAK4 | O96013 | 4/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018737 | 0.80 | ACACB (0.41) | ACACBPAK4PAK1AURKANPY5R | |
| SCHEMBL10144707 | 0.77 | HRH3 (0.41) | ACACBHRH3 | |
| SCHEMBL12888681 | 0.76 | GRIN2B (0.47) | ACACBPAK4PAK1AURKANPY5R | |
| SCHEMBL20000499 | 0.74 | HRH3 (0.42) | ACACBHRH3 | |
| SCHEMBL10188256 | 0.74 | DYRK1A (0.45) | ACACB | |
| SCHEMBL10187134 | 0.73 | NPY5R (0.39) | ACACBPAK4PAK1AURKANPY5R | |
| SCHEMBL15740453 | 0.72 | POLB (0.42) | HRH3 | |
| SCHEMBL12487624 | 0.72 | DYRK1A (0.42) | HRH3 | |
| Hydrochloric Acid SCHEMBL27685768 | 0.70 | DYRK1A (0.41) | HRH3 | |
| SCHEMBL13685055 | 0.70 | ACACB (0.41) | ACACBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |